Merit Medical (MMSI) posts Q3 2025 results and updates full-year guidance
Rhea-AI Filing Summary
Merit Medical Systems, Inc. filed a Form 8-K after issuing a press release with its operating and financial results for the quarter ended September 30, 2025. The company also held a conference call with a live webcast and slide presentation to discuss these third-quarter results and its outlook.
The press release, titled “Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance,” and the conference call slides are provided as Exhibits 99.1 and 99.2. Merit highlights both GAAP and non-GAAP financial measures and states that detailed reconciliations to comparable GAAP figures are included in these materials. The company explains that it does not provide full GAAP guidance for certain metrics because it cannot reasonably predict the impact of acquisition-related items, non-cash amortization, severance, litigation, and regulatory changes on future results.
Positive
- None.
Negative
- None.
Insights
Merit reports Q3 2025 results and updates full-year guidance using GAAP and non-GAAP metrics.
Merit Medical Systems has released its results for the quarter ended September 30, 2025 via press release and an investor conference call. The company also updated its full-year guidance, signaling that management is refining expectations for the remainder of the year based on recent performance and current conditions.
The disclosure emphasizes the use of both GAAP and non-GAAP financial measures, with reconciliations provided in the accompanying press release and slide deck. The company notes it cannot reasonably forecast certain acquisition-related, non-cash, severance, litigation, and regulatory items, which is why it limits GAAP-based forward guidance. This framework means investors need to review the attached exhibits to understand the specific revenue figures, margins, and updated guidance ranges.
Because the core financial details and guidance changes are contained in Exhibits 99.1 and 99.2, the actual impact on valuation depends on the magnitude and direction of those figures. Subsequent reviews of the detailed numbers and reconciliations in the exhibits will determine whether the updated outlook represents a significant shift from prior expectations.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of | (Commission | (I.R.S. Employer | ||
incorporation or organization) | File Number) | Identification No.) |
| ||
(Address of principal executive offices) | (Zip Code) |
(
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On October 30, 2025, Merit Medical Systems, Inc. (“Merit”) issued a press release announcing its operating and financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
On October 30, 2025, Merit is conducting a conference call to discuss its operating and financial results for the quarter ended September 30, 2025. A live webcast and slide presentation will also be available for the conference call on the Merit’s website. A copy of the slide presentation is furnished as Exhibit 99.2 to this report and incorporated herein by reference.
The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K (including the exhibits attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended, or the Exchange Act.
In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), Merit is disclosing non-GAAP financial information in both the press release announcing its operating and financial results and the conference call presentation. Reconciliations of certain of these non-GAAP financial measures to the comparable GAAP financial measures are included in the press release and conference call presentation attached as Exhibit 99.1 and 99.2, respectively, to this report. Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP figures to their GAAP counterparts could be confusing to investors or cause undue reliance.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
EXHIBIT NUMBER |
| DESCRIPTION |
99.1 | Press Release, dated October 30, 2025, entitled “Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance” including unaudited financial information. | |
99.2 | Conference Call Presentation | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MERIT MEDICAL SYSTEMS, INC. | ||
Date: October 30, 2025 | By: | /s/ Brian G. Lloyd |
Brian G. Lloyd | ||
Chief Legal Officer and Corporate Secretary | ||
3
FAQ
What did Merit Medical Systems (MMSI) disclose in this Form 8-K?
Which period do the reported results for Merit Medical Systems (MMSI) cover?
How is Merit Medical Systems (MMSI) sharing its Q3 2025 results with investors?
Does Merit Medical Systems (MMSI) use non-GAAP financial measures in its Q3 2025 disclosure?
Why doesn’t Merit Medical Systems (MMSI) provide full GAAP guidance for all forward-looking metrics?
Are the Q3 2025 results of Merit Medical Systems (MMSI) considered filed or furnished?
